
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cantrixil
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Kazia Therapeutics
Deal Size : $1.0 million
Deal Type : Divestment
Kazia Sells IP And Trademarks Rights For Cantrixil Asset
Details : Vivesto is currently exploring TRX-E-002-1 (cantrixil), a potent and selective third generation benzopyran SMETI inhibitor, preclinically for the treatment of hematological cancers.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 31, 2025
Lead Product(s) : Cantrixil
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Kazia Therapeutics
Deal Size : $1.0 million
Deal Type : Divestment
